Important Update on FDA Changes Concerning Peptides FDA Immunotherapy Approvals in the Second Half of 2025 OncoDaily FDA Removes 14 Peptides from Category 2 to Category 1 Mansi Hukmani posted on the topic LinkedIn Not all peptides are restricted. Here's the breakdown you actually need. The FDA's Category 2 classification affects specific compounded peptides BPC 157, TB 500, CJC 1295 Ipamorelin, AOD 9604, Epithalon, Selank, Semax. Others like Sermorelin